Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2)

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2727-2730

  Joulia, J M ^a,b   Pinguet, F ^a   Ychou, M ^a   Duffour, J ^a   Topart, D ^a   Grosse, P Y ^a,b   Astre, C ^a   Bressolle, Françoise ^a,b,c  

^a Anticancer Center   (France)

^b Lab de Pharmacocinétique   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

5 flourouracil; Metastatic colorectal cancer; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; ASTHENIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NAUSEA; PRIORITY JOURNAL; STOMATITIS; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0030747999     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Door RT, Fritz WL: Cancer Chemotherapy Handbook, Elsevier/North Holland, Amsterdam, 1980 p. 435.
2. Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y, Saito D, Tajiri H, Yamaguchi H, Yoshida S, Yoshimo M, Ohkura H, Yoshimori M, Okazaki N: Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26: 352-354, 1990.
3. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425-432, 1989.
4. The advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. J Clin Oncol 10: 896-903, 1992.
5. Johnson PWM, Thompson PI, Seymour MT, Deasy NP, Thuraisingham RC, Slevin ML, Wrigley PFM: A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 64: 603-605, 1991.
6. de Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, Grange JD, Gonzalez-Canali G, Demuynck B, Louvet C, Seroka J, Dray C, Debray J: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24: 1499-1503, 1988.
7. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, Bedenne L: A prospective randomized trial comparing 5FU bolus with low dose folinic acid (FUFOLId) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proceedings of ASCO 14: A455, 1995.
8. Erlichman C, Fine S, Elhakim T: Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep 70: 903-904, 1986.
9. Harris BE, Song RL, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for a circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
10. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1676-1679, 1988.
11. Thyss A, Milano G, Renee N, Vallicioni, Schneider M, Demard F: Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16: 64-66, 1986.
12. Groeningen CJ, Pinedo HM, Heddes J, Kok R, de Jong PJM, Wattel E, Peters GJ, Lankelma J: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48: 6956-6961, 1988.
13. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987.
14. Trump D, Egorin MJ, Forrest A, Willson JKV, Remick S, Tutsch K: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9: 2027-2035, 1991.
15. Schalhorn, Kuhl M: Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol 19: 82-92, 1992.
16. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-451, 1996.
17. Pinedo HM, Peters GJ: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
18. Collin JM, Dedrick RL, King FG, Speyer JL, Myers CE: Non-linear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharm Ther 28: 235-246, 1980.
19. Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML: Lack of effect of interferon α2a upon fluorouracil pharmacokinetics. Br J Cancer 70: 724-728, 1994.
20. Joulia JM, Pinguet F, Grosse PY, Astre C, Bressolle F: Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography. Application to a pharmacokinetic study. J Chromatogr 1997, in press.
21. Gomeni C, Gomeni R: SIPHAR: An integrated computer system for statistical and pharmacokinetic data analysis. In: Serio A, O'Moore R, Tardini A, Roger FH, eds. Proceedings of the 7th International Congress of Medical Informatics. Europe 87, Rome: European Federation for Medical Informatics, September 1987, pp 507-516.
22. Bertrand M, Doroshow JH, Multhauf P, Blayney DW, Carr BI, Cecchi G, Goldberg D, Leong L, Margolin K, Metter G, Staples R: High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. J Clin Oncol 4: 1058-1061, 1986.